Radiolabeling of bleomycin-glucuronide with 131I and biodistribution studies using xenograft model of human colon tumor in Balb/C mice

Basit Öğe Kaydı
dc.contributor.authorDemiroglu H.
dc.contributor.authorAvcibaşi U.
dc.contributor.authorÜnak P.
dc.contributor.authorMüftüler F.Z.B.
dc.contributor.authorIçhedef Ç.A.
dc.contributor.authorGümüşer F.G.
dc.contributor.authorSakarya S.
dc.date.accessioned2019-10-26T21:45:53Z
dc.date.available2019-10-26T21:45:53Z
dc.date.issued2012
dc.departmentEge Üniversitesien_US
dc.description.abstractBleomycin-glucuronide (BLMG) is the glucuronide conjugate of BLM. In the present study, BLMG was primarily enzymatically synthesized by using a microsome preparate separated from rat liver, labeled with 131I by iodogen method with the aim of generating a radionuclide-labeled prodrug, and investigated its bioaffinities with tumor-bearing Balb/C mice. Quality control procedures were carried out using thin-layer radiochromatography and high-performance liquid chromatography. Tumor growing was carried out by following Caco-2 cell inoculation into mice. Radiolabeling yield was found to be about 65%. Results indicated that 131I-labeled BLMG ( 131I-BLMG) was highly stable for 24 hours in human serum. Biodistribution studies were carried out with male Albino Wistar rats and colorectal adenocarcinoma tumor-bearing female Balb/C mice. The biodistribution results in rats showed high uptake in the prostate, the large intestine, and the spinal cord. In addition to this, scintigraphic results agreed with those of biodistributional studies. Xenography studies with tumor-bearing mice demonstrated that tumor uptakes of 131I-BLM and 131I-BLMG were high in the first 30 minutes postinjection. Tumor-bearing animal studies demonstrated that 131I-BLMG was specially retained in colorectal adenocarcinoma with high tumor uptake. Therefore, 131I-BLMG can be proven to be a promising imaging and therapeutic agent, especially for colon cancer in nuclear medical applications. © Copyright 2012, Mary Ann Liebert, Inc. 2012.en_US
dc.identifier.doi10.1089/cbr.2011.1157en_US
dc.identifier.endpage383en_US
dc.identifier.issn1084-9785
dc.identifier.issue6en_US
dc.identifier.pmid22690908en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage371en_US
dc.identifier.urihttps://doi.org/10.1089/cbr.2011.1157
dc.identifier.urihttps://hdl.handle.net/11454/18530
dc.identifier.volume27en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.relation.ispartofCancer Biotherapy and Radiopharmaceuticalsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subject131Ien_US
dc.subjectBalb/C miceen_US
dc.subjectbiodistributionen_US
dc.subjectbleomycinen_US
dc.subjectbleomycin-glucuronideen_US
dc.subjectCaco-2en_US
dc.subjectglucuronidationen_US
dc.subjectscintigraphyen_US
dc.subjectxenographyen_US
dc.titleRadiolabeling of bleomycin-glucuronide with 131I and biodistribution studies using xenograft model of human colon tumor in Balb/C miceen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu